Janus Henderson Group PLC Increases Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

Janus Henderson Group PLC grew its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 12.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,436,990 shares of the biotechnology company’s stock after buying an additional 156,544 shares during the quarter. Janus Henderson Group PLC’s holdings in Arrowhead Pharmaceuticals were worth $90,119,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Tsfg LLC purchased a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at $25,000. iSAM Funds UK Ltd purchased a new position in Arrowhead Pharmaceuticals in the third quarter worth about $29,000. First Horizon Corp purchased a new position in Arrowhead Pharmaceuticals in the fourth quarter worth about $32,000. WPG Advisers LLC grew its stake in shares of Arrowhead Pharmaceuticals by 384.8% during the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 431 shares during the period. Finally, Hantz Financial Services Inc. grew its stake in shares of Arrowhead Pharmaceuticals by 177.1% during the 4th quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 471 shares during the period. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ARWR has been the topic of several recent research reports. JPMorgan Chase & Co. increased their price objective on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Leerink Partners upped their target price on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a report on Wednesday, June 17th. Morgan Stanley increased their price target on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Royal Bank Of Canada lifted their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Finally, Stifel Nicolaus began coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They set a “buy” rating and a $98.00 price objective for the company. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $96.92.

Insider Activity at Arrowhead Pharmaceuticals

In related news, Director Hongbo Lu sold 2,970 shares of the company’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total transaction of $228,333.60. Following the completion of the transaction, the director owned 52,012 shares in the company, valued at approximately $3,998,682.56. This represents a 5.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Stock Down 3.1%

Shares of ARWR opened at $84.65 on Friday. The business’s 50 day moving average is $79.04 and its 200 day moving average is $70.67. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 1.41. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $15.01 and a 12-month high of $95.49. The company has a market capitalization of $11.92 billion, a PE ratio of -39.37 and a beta of 1.26.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The business had revenue of $73.74 million during the quarter, compared to the consensus estimate of $73.84 million. During the same period in the prior year, the company posted $2.75 EPS. The firm’s revenue for the quarter was down 86.4% compared to the same quarter last year. Research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3.08 earnings per share for the current fiscal year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.